Overview of Compass Therapeutics#
H.C. Wainwright has reaffirmed a Buy rating for Compass Therapeutics (NASDAQ:CMPX) and set a price target of $24.00. This comes as the company has shown impressive stock performance, with a 159% return over the past year, despite its current share price of $1.96 and a market capitalization of $906 million.
Positive Clinical Trial Results#
The firm noted that the drug tovecimig has shown promising results in clinical trials for second-line biliary tract cancer. Specifically, it demonstrated a hazard ratio of 0.44 for progression-free survival, indicating a 56% reduction in the risk of disease progression. The trial also had a crossover rate of 54%, meaning many patients switched from the control group to the treatment group, which can affect the results.
Comparison with Benchmark Trials#
The benchmark for second-line biliary tract cancer treatment is the ABC-06 trial, which reported a median overall survival of 6.2 months and a progression-free survival of about 4 months. While tovecimig showed significant improvements in progression-free survival, it did not meet all secondary endpoints related to overall survival, raising questions about its regulatory approval prospects.
Future Developments and Analyst Insights#
Compass Therapeutics is preparing for a meeting with the FDA regarding a pre-biologics license application, aiming for accelerated approval. The complete trial data will be presented at an upcoming medical conference. Analysts have varying price targets for the stock, ranging from $8 to $30, indicating potential for growth. Despite mixed results from recent trials, firms like Leerink Partners and Stifel have reiterated positive ratings, reflecting confidence in the company's future prospects.